
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine Inc. has demonstrated a significant advancement in its pipeline with LPCN 1154, an oral formulation of brexanolone, which showcases an impressive efficacy profile featuring a rapid onset of action, a treatment duration of 48 hours, and a remission rate of up to 61% at Day 3 with no adverse events related to sedation reported in clinical trials. The company is on track for a topline readout in the second quarter of 2026, bolstering the likelihood of regulatory approval to 50%, indicating a growing confidence in its product offerings. Despite a modest net loss of $3.2 million, the firm's innovations and potential for future revenue streams from its products present a favorable outlook for investors.
Bears say
Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, indicating ongoing financial challenges as the company continues to invest in its drug development pipeline. The company faces significant risks associated with its lead candidate LPCN 1154, including potential failure in clinical trials, obstacles to obtaining regulatory approval, and challenges regarding commercial success due to factors such as reimbursement and competition. Additionally, the prospect of dilution poses further concerns for shareholders, compounding the negative outlook regarding Lipocine's stock performance.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares